Skip to main content Accessibility help

Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study

  • Volker Mall (a1), Florian Heinen (a2), Andrea Siebel (a3), Christoph Bertram (a4), Ulrich Hafkemeyer (a5), Jörg Wissel (a6), Steffen Berweck (a7), Fritz Haverkamp (a8), Günter Nass (a9), Leo Döderlein (a10), Nico Breitbach-Faller (a11), Wilhelm Schulte-Mattler (a12) and Rudolf Korinthenberg (a1)...


Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee–knee distance ‘fast catch’, p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037).


Corresponding author

Children's University Hospital, Department of Neuropaediatrics and Muscular Disorders, University of Freiburg, Mathildenstrasse 1, D-79106 Freiburg, Germany. E-mail:


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed